CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
EditForce
Company Type: Therapeutic development
Main focus: Development of safe and innovative treatments through RNA editing
Company stage: Pre-clinical
Diseases: Central nervous system, muscular, and rare diseases such as myotonic dystrophy type 1 (DM1)
Genome-editing tool: RNA editing
Funding stage: Venture - Series Unknown
Location: Sawara-ku, Fukuoka City, Fukuoka, Japan
Website: https://www.editforce.co.jp/en/
Pipeline: https://www.editforce.co.jp/en/business/
Partners:
EditForce specialises in RNA editing using proprietary pentatricopeptide repeat (PPR) proteins, allowing precise modifications to RNA sequences without altering genomic DNA. The company aims to develop safe and effective targeted treatment for genetic disorders by correcting mutations at the RNA level. EditForce’s pipeline currently consists of two candidates to treat myotonic dystrophy type I and neuronal/cardiac disease.
